logo

  • The Company
    The Company
      • Promore Pharma in Brief
      • Vision and Strategy
      • Market
      • Team
      • Board of Directors
  • Projects
    Projects
      • Project Overview
      • Ensereptide – Prevention of Post-Surgical Adhesions and Scars
      • Ropocamptide – Healing of Chronic Wounds
      • Publications
  • Investors
    Investors
      • Promore Pharma on Nasdaq First North Growth Market
        • Certified Adviser
      • The Share
        • Shareholders
        • Warrant Programs
        • Share capital development
        • Analysts
      • Financial Reports
      • Press Releases
      • Prospectuses
      • Presentations and Events
      • Calendar
      • Subscribe
  • Corporate Governance
    Corporate Governance
      • Corporate Governance
      • General Meeting
        • General Meetings
      • Nomination Committee
        • Nomination Committees
      • The Board of Directors
        • Board of Directors
      • The Management
        • Management
      • Remunerations and Remuneration Committee
      • Auditor and Audit Committee
      • Articles of Association
      • Certificate of Registration
  • Media
    Media
      • Press Releases
      • Imagebank
      • Promore Pharma in Media
      • Subscribe
  • Contact
    Contact
      • Office
      • Investors
      • Media
Svenska
The Company
  • Promore Pharma in Brief
  • Vision and Strategy
  • Market
  • Team
  • Board of Directors
Projects
  • Project Overview
  • Ensereptide – Prevention of Scarring
  • Ropocamptide – Healing of Chronic Wounds
  • Publications
Investors
  • Promore Pharma on Nasdaq First North Growth Market
    • Certified Adviser
  • The Share
    • Shareholders
    • Warrant Programs
    • Share capital development
    • Analysts
  • Financial Reports
  • Press Releases
  • Prospectuses
  • Presentations and Events
  • Calendar
  • Subscribe
Corporate Governance
  • Corporate Governance
  • General Meeting
    • General Meetings
  • Nomination Committee
    • Nomination Committees
  • The Board of Directors
    • Board of Directors
  • The Management
    • Management
  • Remunerations and Remuneration Committee
  • Auditor and Audit Committee
  • Articles of Association
  • Certificate of Registration
Media
  • Press Releases
  • Imagebank
  • Promore Pharma in Media
  • Subscribe
Contact
  • Office
  • Investors
  • Media

Investors

  • Promore Pharma on Nasdaq First North Growth Market
    • Certified Adviser
  • The Share
    • Shareholders
    • Warrant Programs
    • Share capital development
    • Analysts
  • Financial Reports
  • Press Releases
  • Prospectuses
  • Presentations and Events
  • Calendar
  • Subscribe

Contact

Erik Magnusson

 Chief Financial Officer (CFO) +46 70 856 52 45

Presentations and Events

2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • All years
May 17, 2022

Promore Pharma — interim report January-March 2022

May 13, 2022

Invitation to Conference Call regarding Promore Pharma’s Interim Report for the First Quarter 2022

February 16, 2022

Year-end report 2021

February 9, 2022

Invitation to Conference Call regarding Promore Pharma’s Year-end Report 2021

The Company
  • Promore Pharma in Brief
  • Vision and Strategy
  • Market
  • Team
  • Board of Directors
Projects
  • Project Overview
  • Ensereptide – Prevention of Scarring
  • Ropocamptide – Healing of Chronic Wounds
  • Publications
Investors
  • Promore Pharma on Nasdaq First North Growth Market
  • The Share
  • Financial Reports
  • Press Releases
  • Prospectuses
  • Presentations and Events
  • Calendar
  • Subscribe
Corporate Governance
  • Corporate Governance
  • General Meeting
  • Nomination Committee
  • The Board of Directors
  • The Management
  • Remunerations and Remuneration Committee
  • Auditor and Audit Committee
  • Articles of Association
  • Certificate of Registration
Media
  • Press Releases
  • Imagebank
  • Promore Pharma in Media
  • Subscribe
Contact
  • Office
  • Investors
  • Media

Promore Pharma AB. Address: Fogdevreten 2, SE-171 65 Solna, Sweden. Phone: +46 8 124 548 59. E-mail: info@promorepharma.com. Registration number: 556639-6809.

  • Personal data
  • About cookies